STOCK TITAN
  1. Home
  2. News
  3. TXG

10x Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10x Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics stock.

10x Genomics, Inc. (Nasdaq: TXG) is a leading life science technology company based in Pleasanton, California. The company specializes in creating innovative solutions for single cell and spatial biology research, providing researchers with the tools necessary to advance human health by deepening the understanding of complex biological systems.

10x Genomics' product portfolio includes cutting-edge instruments, consumables, and software designed for high-resolution, large-scale analysis of biological systems. Among its notable products are the Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software. The bulk of the company's revenue is generated from the sale of consumables, which are crucial for ongoing research and experimental workflows.

Recently, 10x Genomics launched the GEM-X technology, a significant upgrade to its existing single cell technology. The GEM-X platform offers enhanced performance and reliability, enabling more comprehensive single cell analysis. The company has also introduced the Xenium product line, including the Xenium multi-modal cell segmentation kit and an immuno-oncology gene panel, which expands their single cell spatial analysis capabilities.

Financially, 10x Genomics has demonstrated growth, with 2023 revenue reaching $618.7 million, an increase from the previous year. Although the company reported a net loss for the same period, the launch of new products like the Visium HD Spatial Gene Expression assay and the continued development of the GEM-X technology are expected to drive future growth and adoption among researchers worldwide.

10x Genomics collaborates closely with academic and translational researchers, as well as biopharmaceutical companies, to fuel discoveries in fields such as oncology, immunology, and neuroscience. Their integrated solutions enable scientists to study biological systems at a resolution and scale that aligns with the complexity of biology, making significant contributions to the understanding of health and disease.

To stay up-to-date with 10x Genomics' latest developments, visit their official website at 10xgenomics.com, or follow them on LinkedIn and X (Twitter).

News

10x Genomics Launches Xenium Catalyst Network

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) launches Xenium Catalyst Network with 4 founding members to accelerate access to proof-of-concept data for prospective customers worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
News

Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) published a study in Nature Communications using its industry-leading platforms to analyze human breast tumor microenvironments, showcasing the power of integrating findings and the value of spatial profiling techniques.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
News

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) announced that the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 FFPE tissues compared to NanoString's CosMx and Vizgen's MERSCOPE in a new comparison study. Xenium showed higher sensitivity, on-target calls, and lower false discovery rate, as well as better correlation with reference RNA sequencing data. The platform also accurately measured low-expressing genes, exhibited a distinct tissue marker expression pattern, and performed well at distinguishing cells of distinct lineage and identifying all known cell types from breast and lung tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
News

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

Rhea-AI Summary
10x Genomics, Inc. (TXG) collaborates with NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a comprehensive single cell atlas of the human brain. The collaboration aims to further neuroscience research by profiling the epigenome and whole transcriptome across millions of individual cells from diverse brain samples. The goal is to provide a detailed genetic map of the damage caused in neurodegenerative disorders, facilitating the development of new treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
News

Curio Bioscience Responds to Lawsuit

Rhea-AI Summary
Curio Bioscience (CURIO) is a leading innovator in the life sciences industry, offering high-precision tools. Their Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution. The company is facing litigation from 10x Genomics (TXG) but is confident in their defense against patent infringement allegations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Rhea-AI Summary
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString, Awarded Over $31 Million in Damages: A jury in the U.S. District Court for the District of Delaware unanimously ruled in favor of 10x Genomics in the patent infringement suit against NanoString, awarding over $31 million in damages for willful infringement of seven patents. The ruling is the third against NanoString in six months, confirming serial infringement of 10x patents. Post-trial, 10x intends to seek ongoing royalties, treble damages, attorney's fees, a permanent injunction, and pre- and post-judgment interest. 10x's Chief Legal Officer emphasized the importance of protecting patents and thanked the jury for recognizing 10x's innovation. The ruling is based on extensive evidence, including testimony from key figures. This case is part of a larger legal battle, with another suit pending against NanoString in the U.S. District Court for the District of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
none
News

OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study

Rhea-AI Summary
OWKIN and 10x Genomics have entered into an agreement to incorporate 10x Genomics' spatial omics and single-cell technologies into the MOSAIC project. MOSAIC is a $50 million project that utilizes spatial omics technologies to map tumor structures at single-cell resolution. With the addition of 10x Genomics' Visium technology and Chromium portfolio, MOSAIC aims to unlock transformative discoveries in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News

10x Genomics Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
10x Genomics reports Q3 2023 financial results with revenue of $153.6 million, a 17% increase YoY. Gross margin was 62%, operating expenses increased by 35%, and operating loss was $94.8 million. Net loss was $93.0 million. Cash and cash equivalents were $356.9 million. Full year 2023 revenue guidance raised to $610 million to $625 million, representing 18% to 21% growth over 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
earnings
-
News

10x Genomics to Present at the Stephens 25th Annual Conference

Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Stephens 25th Annual Conference on November 14, 2023. The live webcast can be accessed on the company's website and will be available for replay for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
conferences
News

Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

Rhea-AI Summary
10x Genomics announces the use of the 10x Xenium Analyzer in a study characterizing radiation-resistance mechanisms of diffuse midline gliomas. The study provides insights into clinical response and therapeutic strategies, revealing key transcriptomic changes and cell communication pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none

FAQ

What is the current stock price of 10x Genomics (TXG)?

The current stock price of 10x Genomics (TXG) is $13.29 as of November 21, 2024.

What is the market cap of 10x Genomics (TXG)?

The market cap of 10x Genomics (TXG) is approximately 1.6B.

What does 10x Genomics, Inc. specialize in?

10x Genomics specializes in creating innovative solutions for single cell and spatial biology research, providing tools for high-resolution, large-scale analysis of biological systems.

What are some of the key products of 10x Genomics?

Key products include the Chromium Controller, Reagent Kits, 10x Compatible Products, Informatics Software, and the recently launched GEM-X and Xenium platforms.

What recent technological advancements has 10x Genomics introduced?

10x Genomics recently launched the GEM-X technology, a significant upgrade for single cell analysis, and the Visium HD Spatial Gene Expression assay for high-resolution spatial discovery research.

How has 10x Genomics performed financially in recent years?

In 2023, 10x Genomics reported a revenue of $618.7 million, reflecting a year-over-year increase. The company's continued innovation and product development are expected to drive future growth.

Who are the primary users of 10x Genomics' products?

10x Genomics' products are used by academic and translational researchers as well as biopharmaceutical companies to advance research in fields such as oncology, immunology, and neuroscience.

What is the significance of GEM-X technology?

GEM-X technology offers improved performance and reliability for single cell analysis, enabling more comprehensive research and better understanding of biological complexities.

Where can I find the latest news about 10x Genomics?

For the latest news and updates, visit 10x Genomics' official website at https://www.10xgenomics.com or follow them on LinkedIn and X (Twitter).

What is the focus of 10x Genomics' recent product launches?

Recent product launches focus on enhancing single cell and spatial biology research capabilities, including new assays and technology platforms like GEM-X and Visium HD.

What is the impact of 10x Genomics' products on scientific research?

10x Genomics' products enable high-resolution, large-scale analysis of biological systems, driving breakthroughs and transforming our understanding of health and disease.

How does 10x Genomics contribute to the field of biology?

10x Genomics provides tools that allow researchers to study biological systems at a resolution and scale that matches their complexity, facilitating significant scientific discoveries.

Stock TXG logo
10x Genomics, Inc.

Nasdaq:TXG

TXG Rankings

#2144 Ranked by Market Cap
N/A Ranked by Dividends

TXG Stock Data

1.61B
103.97M
2.17%
94.44%
6.28%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
PLEASANTON